Current Treatment of Pediatric Bladder and Prostate Rhabdomyosarcoma.
PURPOSE OF REVIEW
Rhabdomyosarcoma (RMS) is the most common sarcoma diagnosed in the first 20 years of life; bladder/prostate (BP) RMS accounts for 5% of all cases. Through efforts from multiple cooperative study groups, survival has improved significantly. This article aims to review the complex RMS classification system and treatment of BP RMS, with a focus on developing aspects of treatment.


RECENT FINDINGS
Recent advancements in technology are responsible for most of the progress in RMS treatment. PET-CT scanning has been shown to be superior to conventional metastatic workup. The use of proton beam therapy and brachytherapy to reduce the side effects of radiation is also showing promise. All cooperative oncology groups agree on surgical biopsy for diagnosis and staging of BP RMS. Patients are then grouped and risk classified before receiving chemotherapy. Regardless of local control strategy, oncologic outcomes appear to be similar for BP RMS. Alternative treatment strategies, which remain unproven, include brachytherapy and proton therapy.
['Saltzman|Amanda F|AF|', 'Cost|Nicholas G|NG|']
D000971:Antineoplastic Combined Chemotherapy Protocols D001918:Brachytherapy D002648:Child D003131:Combined Modality Therapy D006801:Humans D008297:Male D000072078:Positron Emission Tomography Computed Tomography D011471:Prostatic Neoplasms D061766:Proton Therapy D012208:Rhabdomyosarcoma D001749:Urinary Bladder Neoplasms
Bladder Prostate Rhabdomyosarcoma Long-term outcomes Treatment morbidity